Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Flixabi

- PMLiVE

Biogen to acquire RayThera in $1bn deal

The acquisition will expand the company’s immunology pipeline

- PMLiVE

Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA

In the study, there were improvements in motor function as well as a slowing of neurodegeneration

- PMLiVE

J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

- PMLiVE

Biogen agrees $850m felzartamab rights deal with TJ Biopharma

The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases

- PMLiVE

MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE

Biogen to acquire Apellis in $5.6bn deal

The deal will enhance Biogen’s growth portfolio in immunology and rare disease

- PMLiVE

Sandoz partners with Samsung Bioepis to develop up to five biosimilars

The agreement will expand the pipeline and builds on an existing partnership

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE

Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus

Therapies like topical steroids manage symptoms but there is currently no cure

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links